liraglutide + insulin detemir

Liraglutide + insulin detemir is a combination therapy used in the management of type 2 diabetes mellitus. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. Insulin detemir is a long-acting basal human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production through activation of the insulin receptor. When co-administered, these agents provide additive glycemic control without significant pharmacokinetic interactions or increased risk of hypoglycemia compared to each agent alone[2][5]. This combination is typically considered when oral antidiabetic agents do not achieve adequate glycemic control.